Definitive Contract 75N93023C00055
Award Date
9/25/23
Potential Completion Date
4/1/26
Potential Value
$9.8M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Abviro LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Bethesda, MD 20814, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
31
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government, to Abviro LLC, a for-profit limited liability company, on September 19, 2016. The contract is for the development of a broad-spectrum antibody therapeutic against flavivirus infections, with a ceiling value of $29,404,716.25 and a completion date of September 30, 2022. The contract type is a Definitive Contract with a Cost Plus Fixed Fee pricing...
This is a $16,927,478.76 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Abvacc, Inc., a for-profit biotechnology company. The contract is to develop a potent therapeutic monoclonal antibody targeting the Marburg virus, a highly pathogenic filovirus. This award aligns with NIAID's efforts to advance medical countermeasures against biodefense and emerging infectious...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This is a $3,860,186.71 cost-plus-fixed-fee task order awarded to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for Phase 1 clinical trials of therapeutics against infectious diseases and was issued under the Therapeutics Against Infectious Diseases Phase 1 indefinite-delivery, indefinite-quantity...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for the "CONDUCT STUDY P210" project. The contract has a ceiling value of $890,036.10 and an ultimate completion date of April 30, 2022. This award is part of the larger Simian Vaccine Evaluation Units 2013-2020 master IDIQ contract, under which ABL...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $548,977.00 cost-plus-fixed-fee contract is for the delivery of services in support of NIAID's infectious disease research and product development initiatives. This award is a task order under an existing Indefinite...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a large for-profit manufacturer of goods. The contract, titled "ESSENTIAL CORE ACTIVITIES III," has a ceiling value of $1,920,166.00 and an ultimate completion date of June 8, 2029. This contract is not set aside for any specific business...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the International AIDS Vaccine Initiative (IAVI) to manufacture influenza virus human challenge material for Phase I and II clinical testing. The contract has a ceiling value of $8,337,685.00 and runs through December 31, 2025. IAVI, a global non-profit organization focused on developing preventive HIV vaccines, will serve as the...
This is a $1,663,985.13 firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract supports the process development and cGMP compliant manufacture of a B19 parvovirus vaccine drug product for use in Phase I/II clinical trials. This contract is part of a larger...